|
|
||||||||
Division of Nuclear Medicine, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan
Correspondence: For reprints contact: B. Shapiro, MB, ChB, PhD, Div. of Nuclear Medicine, Box 021, Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109.
ABSTRACT
Iodine-123-4-amino-3-iodobenzylguanidine ([123I]AIBG), an analog of 123I metaiodobenzylguanidine ([123I]MIBG), has an advantage in having a more rapid and simple synthesis. This, combined with animal data that suggested a greater affinity of the new radiopharmaceutical for the autonomic innervation of the myocardium led us to study the biodistribution of [123I]AIBG in three men with metastatic pheochromocytoma. In all instances, [123I]AIBG revealed the same metastatic deposits shown by [123I]MIBG. Iodine-123 AIBG uptake, however, was greater than [123I]MIBG in lung, gut, and spleen. These higher backgrounds may pose diagnostic problems in some cases.
This article has been cited by other articles:
![]() |
M. A. Moroz, I. Serganova, P. Zanzonico, L. Ageyeva, T. Beresten, E. Dyomina, E. Burnazi, R. D. Finn, M. Doubrovin, and R. G. Blasberg Imaging hNET Reporter Gene Expression with 124I-MIBG J. Nucl. Med., May 1, 2007; 48(5): 827 - 836. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |